A dexamethasone (Dex) sensitizer. SMED-1 was discovered in a screen designed to identify compounds that sensitize Dex-resistant ALL xenografts to Dex.1 The assay employed Dex-resistant ALL-19 cells which are resistant at concentrations up to 850 µM. In contrast ALL-3 cells are sensitive to nanomolar concentrations of Dex (IC50=12 nM).2 SMED-1 displays strong synergism at 10 µM plus 1 µM Dex and exhibits little activity alone (IC50>20 µM). SMED-1 is Dex-synergistic in ALL-3, ALL-4 and ALL-16 xenografts but is antagonistic with ALL-31. Synergy is highest when drugs are given simultaneously.1
* VAT and and shipping costs not included. Errors and price changes excepted
